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than 150 IU FSH daily in ‘poor responders’ embarking on IVF/ICSI
treatment is not effective in terms of increasing the LBR.
Although we recognize the amount of time and dedication spent to
conduct this large clinical trial which challenges the concept of indivi-
dualized controlled ovarian stimulation (iCOS), we firmly believe that
the conclusion of this publication is quite misleading as the term ‘poor
responder’ is inappropriately used for a population that certainly does
not fulfill neither the established ESHRE Bologna POR criteria
(Ferraretti et al., 2011) nor the recently suggested POSEIDON criteria
for predicted POR (Humaidan et al., 2016). Many previous publica-
tions pointed out the misleading results deriving from multiple studies
using multiple POR definitions (Polyzos and Devroey, 2011), and of
course, we acknowledge the fact that the study by van Tilborg et al.
was designed prior to the establishment of the Bologna criteria.
Nevertheless, we are surprised that apparently no reviewer commen-
ted on the confusion of terms and the subsequent misleading advice
regarding the clinical management of the POR patient.
Prior to the study by van Tilborg et al., best clinical practice has been
based on large cohort studies, stratifying patients into poor responders
(<4 oocytes retrieved) and sub-optimal responders (4–9 oocytes
retrieved), and for both groups it was clearly stated that retrieving
more oocytes significantly increases the cumulative LBR (Sunkara
et al., 2011; Drakopoulos et al., 2016). Hence, the current policy is to
adopt ovarian reserve tests, AFC and/or AMH, to tailor the treat-
ment, aiming at the retrieval of as many oocytes as possible in pre-
dicted hypo-responder patients. This policy is now challenged by two
large RCTs (Nyboe Andersen et al., 2017; van Tilborg et al., 2017),
which could not find an increase in LBR, despite the fact that iCOS
resulted in significantly fewer poor responses in both studies (<4 or 5
oocytes retrieved, respectively). However, these studies did not inves-
tigate POR patients according to the established definitions, but rather
sub-optimal responders. Thus, sub-analysis according to the estab-
lished POR definitions, including sub-stratifications by age, should be
performed before drawing conclusions regarding clinical management.
Secondly, we suggest that a daily FSH dose above 300 IU does not
add any additional benefit in terms of ovarian response (Berkkanoglu
and Ozgur, 2010), apart from increasing the cost and, thus, the differ-
ence in consumption and cost between the individualized dosing group
and the standard dosing group. Furthermore, the reader is not
informed about the ratio of rFSH and uFSH used during the trial—and
for which groups. We raise this issue as this might also have intro-
duced a response bias, taking into account the physiological difference
in isoform profiles between rFSH and uFSH (Yding Andersen, 2002).
Moreover, what was the basis of an 18-month follow-up period,
instead of follow-up after the use of all cryopreserved embryos?
Finally, there seems to be a discrepancy between the trial protocol
(Dutch trial register NTR2657) and the publication. According to the
register, patients with AFC = 7 were administered 225 FSH IU daily
whereas in the publication it was stated that these patients were admi-
nistered 450 IU/day?
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Derailing individualized ovarian
stimulation
Sir,
We read with interest the paper by Tilborg that incorporated a post
hoc analysis of the utility of anti-müllerian hormone (AMH) for a cost-
effectiveness analysis (van Tilborg et al., 2017). The authors predicated
the randomized control trial (RCT) and individualization of dose solely
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on antral follicle count, but there are a number of substantial issues that
question the ability to retrospectively draw conclusions on the utility of
AMH to individualize treatment. Specifically, longitudinal measurement
of serum AMH shows during GnRH-agonist downregulation shows
marked and clinically relevant changes, an effect dependent on the dur-
ation of GnRH-agonist treatment (Su et al., 2013, Drakopoulos et al.,
2017). Therefore, serum AMH level should be measured before start of
GnRH-agonist downregulation and not once started, as performed by
Tilborg and colleagues. Secondly, four AMH categories have been devel-
oped, but is unclear what modelling underlies these thresholds.
Particularly AMH of 1.33 to <2.25ng/ml (9.5–18.0 pmol/l) was used to
classify normal responders, but in recent phase II (Arce et al., 2014) and
phase III RCTs (Nyboe Andersen et al., 2017), a poor response to ovar-
ian stimulation was anticipated with AMH values <15.0 pmol/l (<2.1
ng/ml) (Arce et al., 2014). Thirdly, retrospectively predicting the out-
come of individualization of treatment based on AMH assumes equiva-
lence with AFC in their association with oocyte yield. In contrast to
older meta-analyses, several recent multicentre studies demonstrate that
AMH exhibits an almost two-fold higher correlation coefficient with
oocyte yield than that observed for AFC determined across multiple
sites (Nelson et al. 2015) and substantially lower variability (Anderson
et al., 2015). The variability between trial sites in AFC (or indeed in
AMH) for the current study is not presented. Lastly, the authors use
statistical methodology to predict the outcome for the 24% of women
where AMH and AFC were discordant. However, this model incorpo-
rates the applied FSH dose which was based on the AFC but not on
AMH, and the assumption that post hoc modelled predictions can
replace real clinical outcomes is questionable. Collectively, these con-
cerns would suggest that, rather than retrospectively infer conclusions
about the utility of AMH for individualizing treatment from incorrectly
timed samples, evidence from a large scale prospective international mul-
ticentre RCT should be used (Nyboe Andersen et al., 2017).
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Usefulness of individualized FSH,
LH and GH dosing in ovarian
stimulation of women with low
ovarian reserve
Sir,
We read with interest the multicentre prospective study by van
Tilborg et al. (2017) concluding that individualized FSH dosing, based
on antral follicle count (AFC), does not improve live-birth rates or
reduce costs as compared to a standard FSH dose. This is likely to be
true for women with predicted normal response to controlled ovarian
hyperstimulation (COH). As to hyper-responders, individualized FSH
dosing appeared to reduce the risk of mild and moderate ovarian
hyperstimulation syndrome (OHSS). On the other hand, the conclu-
sions related to low and extremely low responders are not clear.
First of all, values of anti-Müllerian hormone (AMH) were included
only retrospectively and were not taken into account in the decision
about patients’ eligibility. Yet, AMH, together with AFC, is an import-
ant predictor of poor ovarian reserve (Ferraretti et al., 2011).
Moreover, the lower limit of AFC for patient inclusion is not men-
tioned, and the authors admit that AFC evaluation may have been sub-
ject to inter-observer variability (van Tilborg et al., 2017). It is thus
important to make clear that their conclusions cannot be applied to
women with poor and extremely poor ovarian reserve.
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